ImpediMed warns sales rebuild could extend cash-flow losses

Commercial reset clouds stronger recurring revenue

ImpediMed Limited (ASX:IPD) delivered higher revenue and recurring income in the September quarter, but the more consequential message was a warning that its commercial overhaul may push out the timing of cash-flow break-even.

Revenue rose 6% from the previous quarter to $3.8 million, while constant-currency Annual Recurring Revenue increased 12% from a year earlier to $16.1 million. Yet BCRL sales fell short of management’s expectations, and Body Composition also underperformed. The company responded with a change in sales leadership and what it described as performance-driven turnover across the sales team.

ImpediMed said it has built an almost entirely new commercial leadership team over the past six months. Erik Johnson became Head of Sales in August, while Dr Nicole Stout is due to join as Chief Clinical Innovation Officer on 1 November. The company is still hiring for open territories, meaning the commercial rebuild is not yet complete.

Recurring revenue rises as contract volumes soften

Core Business Total Contracted Value signed during the quarter fell to $4.4 million from $5.4 million in the June quarter, mainly because fewer contracts were due for renewal. The contracts that were renewed carried an average price increase of 18%, offering some support to the subscription model even as renewal volume weakened.

ImpediMed sold 47 SOZO units globally, including 28 in the United States, compared with 36 units in the previous quarter. The company has 662 units installed at leading US hospitals and Master Services Agreements with 27 major Integrated Delivery Networks, but the latest sales figures do not yet show a broad acceleration in new deployments.

New breast-centre standard creates a 2028 adoption deadline

The company is pointing to a regulatory-style change in US cancer care standards as a longer-term demand driver. The National Accreditation Program for Breast Centres has introduced a requirement for accredited centres to maintain a lymphoedema assessment program for at-risk breast cancer patients, with accredited sites required to comply by January 2028. The standard references bioimpedance spectroscopy as an objective method.

That opportunity sits alongside the August sarcopenia clearance, which expanded SOZO’s stated clinical applications into muscle-loss risk assessment. ImpediMed is positioning the platform beyond breast surgeons, targeting medical oncologists, survivorship programs, supportive care services and oncology service-line leaders. Whether that wider commercial pitch converts into contracts will depend partly on the new sales team’s ability to navigate longer, system-wide purchasing decisions.

Cash runway remains finite despite lower operating costs

Operating cash outflow was $2.5 million for the quarter, down from the previous quarter, while customer receipts were $4.2 million. Staff costs fell to $3.8 million, and ImpediMed said actions aimed at reducing its annualised operating cost base by about $5 million were already visible in the quarter’s figures.

The company finished September with $11.6 million in cash, equivalent to 4.7 quarters of operating cash flow at the reported burn rate. It also has a fully drawn secured $16.5 million facility with SWK Funding LLC, carrying interest of 9.5% plus three-month SOFR and maturing in February 2030. The balance sheet therefore provides time for the commercial changes to take effect, but the company has no unused financing facilities available.

The cash position includes the benefit of the $15.3 million capital raise completed earlier in the year. Management has now cautioned that the ramp-up of new sales staff and the shift towards larger enterprise deals could affect the path to break-even, while saying it is assessing initiatives to mitigate that impact.

Heart Health and weight management remain early-stage bets

Heart Health generated no sales in the quarter, although two studies are enrolling patients at a health system with 44 cardiac clinics and another customer in Connecticut has begun enrolment. ImpediMed said spending in the segment would remain deliberately paced until commercial traction justifies greater investment.

Body Composition generated sales but also missed expectations. The company is pursuing opportunities in primary care, sports medicine and research, wellness and longevity, and medically managed weight loss, while seeking larger strategic partners to improve scale. These initiatives broaden the potential market for SOZO, but they also add execution demands at a time when the core BCRL sales operation is being rebuilt.